Our Patents

As of January 2018, Biocept’s liquid biopsy technologies are protected by 22 issued patents in the US, EU, Australia, China, Japan, South Korea, as well as other countries. This includes worldwide patent protection on our highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs).

The Biocept CTC microfluidic channel is unique compared to other cell capture devices in that it uses a unique irregular arrangement of multiple sized posts that are designed to disrupt internal stream-lines for superior cell capture. Additionally, the interior of the microchannel is chemically derivatized to enable the capture of CTCs tagged with cancer specific antibodies. Furthermore, the microfluidic channel is clear glass on one side. This permits direct

Our Patents

As of January 2018, Biocept’s liquid biopsy technologies are protected by 22 issued patents in the US, EU, Australia, China, Japan, South Korea, as well as other countries. This includes worldwide patent protection on our highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs).

The Biocept CTC microfluidic channel is unique compared to other cell capture devices in that it uses a unique irregular arrangement of multiple sized posts that are designed to disrupt internal stream-lines for superior cell capture. Additionally, the interior of the microchannel is chemically derivatized to enable the capture of CTCs tagged with cancer specific antibodies. Furthermore, the microfluidic channel is clear glass on one side. This permits direct

Get In Touch

5810 Nancy Ridge Dr., Suite 150
San Diego, CA 92121
T: 858.320.8200
Toll-free: 888.332.7729
F: 858.320.8225
E: info@biocept.com